apolipoprotein C-III

ap·o·lip·o·pro·tein C-III

an apolipoprotein found in VLDL, HDL, and chylomicrons. It inhibits several lipases, including lipoprotein lipase.

APOC3

A gene on chromosome 11q23.1-q23.2 that encodes apolipoprotein C-III, a very low-density lipoprotein (VLDL) protein that inhibits lipoprotein and hepatic lipases; it is thought to delay catabolism of triglyceride-rich particles.

apolipoprotein C-III

An 8.7 kD protein and major constituent of chylomicrons and VLDL; it is a cofactor for sphingomyelinase, an inhibitor of lipoprotein lipase, may activate lecithin; cholesterol acyltransferase and modulate uptake of TG-rich remnants by hepatic receptors; Pts with apoC-III deficiency have an ↑ risk of CAD
Mentioned in ?
References in periodicals archive ?
WAYLIVRA is designed to reduce the production of apolipoprotein C-III (apoC-III), a protein produced in the liver that plays a central role in the regulation of plasma triglycerides.
ARO-APOC3 is a subcutaneously administered RNAi therapeutic targeting apolipoprotein C-III (APOC3) currently being developed as a potential treatment for patients with severe hypertriglyceridemia and FCS.
Arrowhead Pharmaceuticals announced the presentation of new preclinical data on its expanding pipeline of RNA interference therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets angiopoietin-like protein 3, and ARO-APOC3, which targets apolipoprotein C-III. The invited lecture, titled "The promise of RNA interference as a therapeutic approach for treatment of cardiovascular diseases," was presented at the Vascular Discovery: From Genes to Medicine - Scientific Sessions 2018, a symposium organized by the American Heart Association.
AKCEA-APOCIII-LRx inhibits the production of apolipoprotein C-III (ApoC-III) for the broad population of patients who have cardiometabolic disease due to their elevated triglyceride levels and ApoC-III.
Apolipoprotein C-III (apoC-III) is secreted with VLDL and becomes distributed among circulating lipoproteins [11] conferring harmful properties resulting in ACVD [3, 12].
Apolipoprotein C-III is a potent inhibitor, whereas the apolipoprotein C-II is an activator of lipoprotein lipase, and for the normal functioning lipoprotein lipase requires the presence of apoC-II, as a cofactor [61].
The study by Harvard School of Public Health (HSPH) researchers is the first research to show that a small protein, apolipoprotein C-III (apoC-III), that sometimes resides on the surface of HDL cholesterol may increase the risk of heart disease and that HDL cholesterol without this protein may be especially heart protective.
Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
Other atherogenic lipoprotein particles, including chylomicron and VLDL remnants, abnormal remnant composition, and increased apolipoprotein C-III complicate the metabolic syndrome picture as well, said Dr.
(NASDAQ: ARWR) has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment of hypertriglyceridemia, the company said.
(NASDAQ: ARWR) has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment of hypertriglyceridemia, the company said.
Of the 18 differentially displayed proteins, 12 proteins (a-1B-glycoprotein, keratin type II, neurofilament triplet L protein, vitamin D-binding protein precursor, protease C1 inhibitor precursor, keratin type I cytoskeleton, complement factor B, complement C1r subcomponent precursor, transthyretin precursor, zinc finger protein 792, kininogen-1 precursor, and PRAME family member 7) decreased in concentration after TCC exercise; 4 proteins (complement factor H, apolipoprotein C-III precursor, complement C3 precursor, and [[alpha].sub.2]-macroglobulin) increased in concentration after TCC exercise; and 2 proteins (apolipoprotein A-I precursor and serotransferrin precursor) exhibited an increase or a decrease in the concentrations of their different isoforms.